Business
Waters Corporation (NYSE: WAT) Reports Second Quarter 2025 Financial Results
Waters Corporation (NYSE: WAT), today announced its financial results for the second quarter of 2025.
About this update from Waters Corporation
[{"type":"text","content":"Highlights","length":10,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Sales of $771 million exceeded guidance range; grew 9% as reported and 8% in constant currency","length":94,"tagName":"p"}]},{"val":[{"type":"text","content":"GAAP EPS of $2.47 and non-GAAP EPS of $2.95, above mid-point of guidance range ","length":78,"tagName":"p"}]},{"val":[{"type":"text","content":"Instruments grew mid-single-digits in constant currency, led by high-single-digit LC and MS growth – with continued strength in instrument replacement, particularly among large pharma and CDMO customers","length":202,"tagName":"p"}]},{"val":[{"type":"text","content":"Recurring revenue grew 11% in constant currency, with 9% service growth and double-digit chemistry growth","length":105,"tagName":"p"}]},{"val":[{"type":"text","content":"In constant currency, Pharma grew 11% and Industrial grew 6%, while Academic & Government declined 3%, performing better than expected","length":138,"tagName":"p"}]},{"val":[{"type":"text","content":"Raising full-year 2025 constant currency sales growth guidance to +5.5% to +7.5% and raising full-year 2025 non-GAAP EPS guidance to $12.95 to $13.05","length":149,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":766,"olType":false},{"type":"text","content":"Second Quarter 2025","length":19,"tagName":"p"},{"type":"text","content":"MILFORD, Mass., Aug. 4, 2025 /PRNewswire/ -- Waters Corporation (NYSE: WAT), today announced its financial results for the second quarter of 2025.","length":151,"tagName":"p"},{"type":"text","content":"Sales for the second quarter of 2025 were $771 million, an increase of 9% as reported and 8% in constant currency, compared to sales of $709 million for the second quarter of 2024.","length":180,"tagName":"p"},{"type":"text","content":"On a GAAP basis, diluted earnings per share (EPS) for the second quarter of 2025 was $2.47, compared to $2.40 for the second quarter of 2024. Non-GAAP EPS for the second quarter of 2025 grew 12% to $2.95, compared to $2.63 for the second quarter of 2024.","length":254,"tagName":"p"},{"type":"text","content":""Our team continues to execute extremely well and we delivered excellent results again this quarter, driven by robust instrument replacement trends–particularly among large pharma and CDMO customers," said Dr. Udit Bat...